Inari Ōkami

Inari Collaboration with Eden Enterprise Expands Access to Corn Genetics

Retrieved on: 
Tuesday, October 12, 2021

CAMBRIDGE, Mass., Oct. 12, 2021 /PRNewswire/ -- Inari , the SEEDesign company, announced a strategic collaboration with Eden Enterprise, Inc. that enables access to Stine's elite corn breeding program to further advance the development of unique and competitive products.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 12, 2021 /PRNewswire/ -- Inari , the SEEDesign company, announced a strategic collaboration with Eden Enterprise, Inc. that enables access to Stine's elite corn breeding program to further advance the development of unique and competitive products.
  • "We see tremendous potential with gene editing for our corn and soybean breeding programs," said Harry Stine, president of Eden Enterprise.
  • Stine's unique approach to corn breeding is driving rapid performance gains in the market andthe collaboration announced today further builds on the agreement announced in May with the soybean breeding program.
  • "Inari is committed to building nature-positive solutions that enhance productivity in order to build a more sustainable food system.

Inari Medical to Announce Second Quarter 2021 Financial Results

Retrieved on: 
Tuesday, July 27, 2021

IRVINE, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today it will release its second quarter financial results on Tuesday, August 10, 2021.

Key Points: 
  • IRVINE, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today it will release its second quarter financial results on Tuesday, August 10, 2021.
  • In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • The live webinar of the call may be accessed by visiting the Events Section of the Inari investor relations website at ir.inarimedical.com.
  • Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.

Inari Broadens Access to Soybean Genetics Through Collaboration with Mertec and MS Technologies

Retrieved on: 
Friday, May 21, 2021

b'CAMBRIDGE, Mass., May 21, 2021 /PRNewswire/ -- Inari, the SEEDesignTM company, announced a strategic collaboration with Mertec, LLC and M.S.

Key Points: 
  • b'CAMBRIDGE, Mass., May 21, 2021 /PRNewswire/ -- Inari, the SEEDesignTM company, announced a strategic collaboration with Mertec, LLC and M.S.
  • We\'re excited about the opportunity this collaboration provides to continue unlocking the untapped potential in seed.
  • With a diverse genetic base, Inari can harness the power of artificial intelligence and gain a true understanding of the complexities and opportunities of nature.
  • Through its SEEDesign platform, Inari unlocks new possibilities to bring step-change products to market.

Dr. Sophie V. Vandebroek, Noted Tech Leader, Joins Inari Board of Directors

Retrieved on: 
Tuesday, April 20, 2021

She recently founded Strategic Vision Ventures, a strategic advisory firm, where she shares her expertisein developing innovative concepts from fundamental research to commercial offerings.

Key Points: 
  • She recently founded Strategic Vision Ventures, a strategic advisory firm, where she shares her expertisein developing innovative concepts from fundamental research to commercial offerings.
  • Vandebroek serves as an independent nonexecutive director on the boards of IDEXX Laboratories and Wolters Kluwer N.V. and is a trustee at the Boston Museum of Science.
  • "She is a deeply experienced leader whose knowledge complements our momentum in the areas of predictive design and multiplex gene editing.
  • Based in Cambridge, Massachusetts, with development sites in West Lafayette, Indiana, and Ghent, Belgium, Inari is a growing team of more than 180employees.

Inari Medical to Announce Fourth Quarter and Full Year 2020 Financial Results

Retrieved on: 
Tuesday, February 23, 2021

IRVINE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today it will release financial results for the fourth quarter and full year 2020 after market close on Tuesday, March 9, 2021.

Key Points: 
  • IRVINE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today it will release financial results for the fourth quarter and full year 2020 after market close on Tuesday, March 9, 2021.
  • On the same day, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • The live webinar of the call may also be accessed by visiting the Events section of Inari's website at ir.inarimedical.com.
  • Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.

Inari Medical Reports Preliminary Fourth Quarter 2020 Revenue

Retrieved on: 
Wednesday, January 13, 2021

IRVINE, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quarter 2020 revenue.

Key Points: 
  • IRVINE, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quarter 2020 revenue.
  • Preliminary Fourth Quarter Revenue and Business Highlights:
    Preliminary unaudited revenue is expected to be in the range of $47.9 million to $48.9 million in the fourth quarter of 2020, a 141% to 146% increase over the prior year period and 24% to 26% increase over the third quarter of 2020.
  • The company completed approximately 4,600 procedures in the fourth quarter, a 156% increase over the prior year period and a 24% increase over the third quarter of 2020.
  • We are pleased with our procedural growth in the fourth quarter and the opportunity to save and transform the lives of VTE patients, especially in the face of the challenges presented by the pandemic, said Bill Hoffman, Chief Executive Officer of Inari Medical.

Inari Expands Board of Directors with Appointment of Bob Bechek

Retrieved on: 
Tuesday, January 5, 2021

CAMBRIDGE, Mass., Jan. 5, 2021 /PRNewswire/ --Inari, a biotech seed company, today announced that Bob Bechek has been appointed to its board of directors.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 5, 2021 /PRNewswire/ --Inari, a biotech seed company, today announced that Bob Bechek has been appointed to its board of directors.
  • Bechek is a partner and former worldwide managing director (CEO) and board chair of consulting firm Bain & Company.
  • His appointment, effective Jan. 1, 2021, brings the Inari board to seven members.
  • "Bob joins the Inari board at a very exciting time and his experience in the technology sector will be very helpful to us," said Michael Mack, Inari executive chairman.

Inari Medical Reports Third Quarter 2020 Financial Results

Retrieved on: 
Thursday, November 12, 2020

IRVINE, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its third quarter ended September 30, 2020.

Key Points: 
  • IRVINE, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its third quarter ended September 30, 2020.
  • Revenue was $38.7 million for the third quarter of 2020, compared to $25.4 million for the prior quarter and $14.2 million for the third quarter of 2019.
  • Due to uncertainty surrounding the COVID-19 pandemic, Inari Medical will not provide financial guidance for the remainder of 2020 at this time.
  • Inari Medical will host a conference call to discuss the third quarter financial results after market close on Thursday, November 12, 2020 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Inari Medical Appoints Kevin Strange as VP of Strategy and Business Development and Angela Ahmad as General Counsel

Retrieved on: 
Thursday, November 12, 2020

IRVINE, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the appointment of Kevin Strange as VP of Strategy and Business Development, and Angela Ahmad as General Counsel.

Key Points: 
  • IRVINE, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the appointment of Kevin Strange as VP of Strategy and Business Development, and Angela Ahmad as General Counsel.
  • Strange will be responsible for Inaris corporate strategy and business development initiatives.
  • We could not be more excited for Kevin and Angela to join us.
  • Kevin comes to us with deep experience not only in strategy and business development, but also in the peripheral vascular space more broadly.

Inari Medical to Announce Third Quarter 2020 Financial Results

Retrieved on: 
Thursday, October 29, 2020

IRVINE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari) today announced it will release financial results for the third quarter of 2020 after market close on Thursday, November 12, 2020.

Key Points: 
  • IRVINE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari) today announced it will release financial results for the third quarter of 2020 after market close on Thursday, November 12, 2020.
  • On the same day, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights.
  • The live webinar of the call may also be accessed by visiting the Events section of Inari's website at ir.inarimedical.com.
  • Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.